Press releases – Oncopeptides

New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated – results expected H1-2021

June 1, 2020 - Regulatory press release

STOCKHOLM — June 1, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are...

Number of shares and votes in Oncopeptides

May 29, 2020 - Regulatory press release

Stockholm —May 29, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the dir...

Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic

May 28, 2020 - Regulatory press release

STOCKHOLM — May 28, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary recruitment pause due to the COV...

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

May 26, 2020 - Regulatory press release

Stockholm, Sweden – 26 May 2020 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Interim Report Q1 2020

May 26, 2020 - Regulatory press release

Summary Financial overview January 1 – March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, before and after dilution, was SEK 5.37 (...

Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma – 450 patients included

May 22, 2020 - Regulatory press release

STOCKHOLM — May 22, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple mye...

Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)

May 6, 2020 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA,...

Oncopeptides intends to carry out a directed share issue

May 5, 2020 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA,...

Oncopeptides Annual Report 2019

April 28, 2020 - Regulatory press release

Stockholm – April 28, 2020 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company's website. The report summarizes the company's bus...

Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study

March 26, 2020 - Regulatory press release

STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple mye...

Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program

March 20, 2020 - Regulatory press release

STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronavirus (COVID-19) pandemic. Most imp...

Interim Report Q4 2019

February 20, 2020 - Regulatory press release

Summary Financial overview October 1 – December 31, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 244,9 M (loss: 112.0) Loss per share, before and after dilution, was SEK 4.42 (...